Comparative Pharmacology
Head-to-head clinical analysis: DERMA SMOOTHE FS versus METI DERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DERMA SMOOTHE FS versus METI DERM.
DERMA-SMOOTHE/FS vs METI-DERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluocinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit pro-inflammatory cytokines and reduce inflammation, vasodilation, and edema.
METI-DERM contains methylprednisolone aceponate, a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit pro-inflammatory cytokines, phospholipase A2, and prostaglandin synthesis, thereby reducing inflammation, pruritus, and vasodilation.
Apply topically as a thin film to affected areas twice daily. Maximum weekly dose should not exceed 60 g.
Apply a thin film topically to affected area once or twice daily.
None Documented
None Documented
Terminal elimination half-life: 24-36 hours (systemic absorption after topical application); clinical context: prolonged with hepatic impairment.
Terminal elimination half-life: 6–8 hours in healthy adults; prolonged to 12–15 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal (90%) as inactive metabolites; <5% unchanged. Biliary/fecal excretion accounts for <10%.
Renal: ~60% as unchanged drug and metabolites; biliary/fecal: ~35% as metabolites and unchanged drug; minor respiratory elimination.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid